A mammalian two-hybrid system for adenomatous polyposis coli-mutated colon cancer therapeutics.

Colon cancer cells frequently lose expression of the tumor suppressor adenomatous polyposis coli (APC). As result, beta-catenin accumulates and activates transcription of Tcf-responsive genes. Here we describe a novel mammalian two-hybrid system that selectively kills APC-mutated cells. This system consists of GAL4/beta-catenin, VP16/Tcf4, and a gene that is transcribed when GAL4 and VP16 associate. In APC-mutated human colon cancer cells, such as SW480, GAL4/beta-catenin accumulates, and in the presence of VP16/Tcf4, induces high levels of expression of the reporter gene. Expression of wild-type APC reduced GAL4/beta-catenin and intact beta-catenin levels and inhibited reporter gene expression. In colon cancer cells such as SW48 that have wild-type APC, GAL4/beta-catenin was degraded, and expression levels of the output gene were low. Replacement of the reporter gene with a suicide gene resulted in selective killing of SW480 cells. This system may be applicable for broader use of gene therapy by targeting diseases that involve protein degradation.

[1]  P. Laurent-Puig,et al.  Sequence of molecular genetic events in colorectal tumorigenesis. , 1999, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[2]  M. Taketo,et al.  Intestinal polyposis in mice with a dominant stable mutation of the β‐catenin gene , 1999, The EMBO journal.

[3]  K. Kinzler,et al.  PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.

[4]  Frank McCormick,et al.  β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.

[5]  Stephen J. Elledge,et al.  The SCFβ-TRCP–ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro , 1999 .

[6]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[7]  Bert Vogelstein,et al.  Mutational Analysis of the APC/β-Catenin/Tcf Pathway in Colorectal Cancer , 1998 .

[8]  T. Noda,et al.  Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. , 1997, Science.

[9]  I. Verma,et al.  Gene therapy - promises, problems and prospects , 1997, Nature.

[10]  Jörg Stappert,et al.  β‐catenin is a target for the ubiquitin–proteasome pathway , 1997 .

[11]  Hans Clevers,et al.  Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC , 1997, Science.

[12]  K. Kinzler,et al.  Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma , 1997, Science.

[13]  P. Polakis,et al.  Deletion of an amino-terminal sequence beta-catenin in vivo and promotes hyperphosporylation of the adenomatous polyposis coli tumor suppressor protein , 1996, Molecular and cellular biology.

[14]  Paul Polakis,et al.  Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly , 1996, Science.

[15]  P. Polakis,et al.  Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Fearon,et al.  Karyoplasmic interaction selection strategy: a general strategy to detect protein-protein interactions in mammalian cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  K. Kinzler,et al.  Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. , 1991, Science.

[18]  S. Altschul,et al.  Identification of FAP locus genes from chromosome 5q21. , 1991, Science.

[19]  C. Dang,et al.  Intracellular leucine zipper interactions suggest c-Myc hetero-oligomerization , 1991, Molecular and cellular biology.